不同剂量的雷贝拉唑三联疗法根除幽门螺杆菌的疗效和费用分析

目的 :观察不同剂量的雷贝拉唑为基础的三联疗法根除幽门螺杆菌 (Hp)的疗效与药品费用。方法 :以雷贝拉唑 10mg ,每日 1次为基础的三联疗法为研究组 (A组为 4 3例 ) ,以雷贝拉唑 10mg或兰索拉唑 30mg ,每日 2次为基础的三联疗法为对照组 (B组为 6 0例 ;C组为 5 7例 ) ,观察 3组间的不良反应、Hp根除率和治疗费用。结果 :不良反应的总发生率为 33.8% ,其中A组为 30 % ,B组为 33% ,C组为 37% ,3组比较无显著差异 (P >0 .0 5 )。Hp根除率A组为 91% ,B组为 92 % ,C组为 82 % ,3组比较无显著意义差异 (P >0 .0 5 )。A组的费用明显低于B组和C组。结论 :雷贝拉唑 10mg ,每日 1次为基础的三联疗法是一种疗效较佳且药品费用低的Hp根除方案。

Analysis of effects and costs of different dosage of rabeprazole triple therapy in eradication of Helicobecter pylori

AIM: To investigate the effects and costs of different dosage of rabeprazole triple therapy in eradicating Helicobacter pyroli(Hp). METHODS:The study group was rabeprazole-based triple therapy, (rabeprazole 10 mg, qd). That was group A(n=43).The control groups were triple therapy based on rabeprazole (10 mg, bid) or lansoprazole(30 mg, bid). They were group B (n=60) and group C(n=57). The adverse drug reaction, rate of eradication Hp, costs among three groups were observed. RESULTS: The total rate of adverse reaction was 33.8%, that was 30% in group A, 33% in group B, 37% in group C, respectively.There was no significant difference among them(P>0.05). Eradication rate of Hp was 91% in group A, 92% in group B and 82% in group C. But there was no significant difference among three groups (P>0.05). The cost of group A was much lower than that of group B and C. CONCLUSION:The triple therapy based on rabeprazole 10 mg qd is a better way of eradication of Hp than the others in their effect and cost.